Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701275 | 0.84 | HTR2A (0.71) | HSD11B1LMNAKMT2ASMN1; SMN2HTT | |
| SCHEMBL13701329 | 0.80 | HTR2A (0.57) | HSD11B1LMNAKMT2ASMN1; SMN2HTT | |
| SCHEMBL14495099 | 0.78 | ALDH1A1 (0.78) | KMT2ASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL14495101 | 0.76 | PKM (0.59) | LMNAKMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL5968704 | 0.76 | HTR2A (0.57) | HSD11B1LMNAKMT2ASMN1; SMN2HTT | |
| SCHEMBL14495114 | 0.75 | HTR2A (0.64) | HTR2AGRM2 | |
| SCHEMBL13701287 | 0.74 | L3MBTL1 (0.75) | LMNAKMT2ASMN1; SMN2HTTMAPT | |
| SCHEMBL14495107 | 0.74 | HTR2A (0.63) | HTR2AGRM2 | |
| SCHEMBL6024823 | 0.74 | HTR2B (0.68) | HTR2AGRM2L3MBTL1 | |
| SCHEMBL13701291 | 0.74 | HTR2B (0.68) | HTR2AGRM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | HSD11B1 466/4885LMNA 4868/4885KMT2A 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.